[go: up one dir, main page]

BR9913742A - Inibidores de fator viia - Google Patents

Inibidores de fator viia

Info

Publication number
BR9913742A
BR9913742A BR9913742-9A BR9913742A BR9913742A BR 9913742 A BR9913742 A BR 9913742A BR 9913742 A BR9913742 A BR 9913742A BR 9913742 A BR9913742 A BR 9913742A
Authority
BR
Brazil
Prior art keywords
factor viia
viia inhibitors
inhibitors
fviia
preparation
Prior art date
Application number
BR9913742-9A
Other languages
English (en)
Inventor
Pavel Safar
Alena Safarova
Peter Wildgoose
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9913742A publication Critical patent/BR9913742A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE FATOR VIIa"<D>. A presente invenção refere-se a novos compostos, sua preparação, seu uso e composições farmacêuticas contendo os compostos que têm um efeito antitrombótico forte através da inibição reversível do fator VIIa (FVIIa) de coagulação do sangue ativado.
BR9913742-9A 1998-09-15 1999-09-02 Inibidores de fator viia BR9913742A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98117506A EP0987274A1 (en) 1998-09-15 1998-09-15 Factor VIIa Inhibitors
PCT/EP1999/006449 WO2000015658A1 (en) 1998-09-15 1999-09-02 FACTOR VIIa INHIBITORS

Publications (1)

Publication Number Publication Date
BR9913742A true BR9913742A (pt) 2001-06-05

Family

ID=8232644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913742-9A BR9913742A (pt) 1998-09-15 1999-09-02 Inibidores de fator viia

Country Status (25)

Country Link
US (1) US6287794B1 (pt)
EP (2) EP0987274A1 (pt)
JP (1) JP4537581B2 (pt)
KR (1) KR100665490B1 (pt)
CN (1) CN1203087C (pt)
AR (1) AR027814A1 (pt)
AT (1) ATE460424T1 (pt)
AU (1) AU760580B2 (pt)
BR (1) BR9913742A (pt)
CA (1) CA2344048A1 (pt)
CZ (1) CZ300249B6 (pt)
DE (1) DE69942123D1 (pt)
HK (1) HK1040253B (pt)
HU (1) HUP0103851A3 (pt)
ID (1) ID28494A (pt)
IL (2) IL141415A0 (pt)
MY (1) MY125150A (pt)
NO (1) NO328523B1 (pt)
NZ (1) NZ510509A (pt)
PL (1) PL203227B1 (pt)
RU (1) RU2223967C2 (pt)
TR (1) TR200100766T2 (pt)
TW (1) TW576839B (pt)
WO (1) WO2000015658A1 (pt)
ZA (1) ZA200101861B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
NZ512736A (en) * 1999-01-13 2003-11-28 Genentech Inc Serine protease inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
JP3859512B2 (ja) * 1999-10-01 2006-12-20 中外製薬株式会社 血液凝固関連疾患の予防及び治療
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
EP1162194A1 (en) * 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
DK1383731T3 (da) 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
JP4274522B2 (ja) 2000-12-06 2009-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｘａ因子阻害剤としてのグアニジンおよびアミジン誘導体
EP1364960A4 (en) 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
EP1270551A1 (en) * 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7604932B2 (en) * 2002-11-13 2009-10-20 Haematologic Technologies, Inc. Assay for tissue factor in a sample
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1628954A2 (en) 2003-05-20 2006-03-01 Genentech, Inc. Acylsulfamide inhibitors of factor viia
EP1626966A1 (en) 2003-05-20 2006-02-22 Genentech, Inc. Benzofuran inhibitors of factor viia
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
PL1748781T3 (pl) * 2004-05-27 2013-05-31 Baxter Int Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
KR20100031732A (ko) 2007-07-10 2010-03-24 사노피-아벤티스 항혈전 활성을 갖는 말론아미드 유도체
CN101981050A (zh) * 2008-01-23 2011-02-23 诺沃-诺迪斯克保健股份有限公司 新的凝血因子抑制剂
WO2012104418A2 (en) * 2011-02-04 2012-08-09 Octapharma Ag Method for inactivation/removal of coagulation factors by precipitation
CN112996528B (zh) * 2018-09-11 2025-01-07 安必圣有限责任公司 肽及其医学用途
AU2019340465B2 (en) * 2018-09-11 2025-08-14 Anbition S.R.L. Peptides and medical uses thereof
US20220380478A1 (en) 2019-07-01 2022-12-01 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
EP4274587A1 (en) 2021-01-06 2023-11-15 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
GB202209228D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
EP0391999A4 (en) * 1988-09-23 1991-03-13 Corvas, Inc. Peptidyl inhibitors of the initiation of coagulation
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE69413817T2 (de) * 1993-06-18 1999-06-10 Nycomed Imaging As, Oslo Faktor vii-peptide
US5849510A (en) * 1994-04-26 1998-12-15 Selectide Corporation Factor Xa inhibitors
SI9520044B (sl) * 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
RU2097033C1 (ru) * 1994-09-30 1997-11-27 Московская государственная академия тонкой химической технологии им.М.В.Ломоносова Имидазолсодержащие ингибиторы катепсин g-индуцированной агрегации тромбоцитов
US5837684A (en) * 1995-06-07 1998-11-17 Nycomed Imaging As Peptides
WO1997030971A1 (en) * 1996-02-22 1997-08-28 The Du Pont Merck Pharmaceutical Company M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
ZA200101861B (en) 2001-10-22
IL141415A (en) 2006-09-05
NO20011293L (no) 2001-05-04
EP1114061A1 (en) 2001-07-11
CZ300249B6 (cs) 2009-04-01
CN1318069A (zh) 2001-10-17
PL346781A1 (en) 2002-02-25
HK1040253A1 (en) 2002-05-31
HUP0103851A2 (hu) 2002-04-29
PL203227B1 (pl) 2009-09-30
DE69942123D1 (de) 2010-04-22
ID28494A (id) 2001-05-31
HK1040253B (zh) 2005-09-02
MY125150A (en) 2006-07-31
TR200100766T2 (tr) 2001-10-22
NO20011293D0 (no) 2001-03-14
CA2344048A1 (en) 2000-03-23
AU760580B2 (en) 2003-05-15
CN1203087C (zh) 2005-05-25
JP2002524571A (ja) 2002-08-06
EP0987274A1 (en) 2000-03-22
AU5972399A (en) 2000-04-03
ATE460424T1 (de) 2010-03-15
RU2223967C2 (ru) 2004-02-20
NZ510509A (en) 2002-09-27
NO328523B1 (no) 2010-03-08
KR100665490B1 (ko) 2007-01-10
IL141415A0 (en) 2002-03-10
HUP0103851A3 (en) 2002-05-28
KR20010075130A (ko) 2001-08-09
EP1114061B1 (en) 2010-03-10
JP4537581B2 (ja) 2010-09-01
TW576839B (en) 2004-02-21
US6287794B1 (en) 2001-09-11
CZ2001914A3 (en) 2001-06-13
AR027814A1 (es) 2003-04-16
WO2000015658A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
BR9913742A (pt) Inibidores de fator viia
TR199903193T1 (xx) Mukozaya uygulanmak �zere farmas�tik kompozisyon.
UY27404A1 (es) Composición cristalina que contiene escitalopram
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
IT1295694B1 (it) Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
BR0112252A (pt) Derivados de pirazole
DK0670310T3 (da) Bisulfitaddukt af argininaldehyder egnet som thrombininhibitorer og som antikoagulanter
PT799209E (pt) Novas sulfonamidas
CA2191789A1 (fr) Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
DK1079807T3 (da) Anvendelse af præparater til tilförsel af antiseptiske midler og/eller midler, som fremmer heling af sår, til de nedre luftveje
ATE165971T1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
HUP9901586A2 (hu) Antifungális szert és acetátpuffert tartalmazó készítmények és alkalmazásuk
ATE173923T1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
TR200100239T2 (tr) Matris metaloproteinazların önlenmesinde kullanılan trisiklik sülfonamitler ve türevleri.
BR0115518A (pt) Kit de repinotan
BR9706386A (pt) Antagonistas do receptor de vitronectina, sua preparação e seu us0
BR0012475A (pt) Compostos de titânio, preparação e utilização dos mesmos
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ATE234359T1 (de) Fusionsproteine bestehend aus gewebefaktor- kunitzdomäne als inhibitoren des faktors viia
TR200200841T2 (tr) Mukozaya uygulama için, siklesonid içeren farmasötik kompozisyon
TR199701121T1 (xx) Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri.
FR2773712B1 (fr) Composition pharmaceutique comprenant au moins un inhibiteur de l&#39;aminopeptidase a

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements